Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification

Molecular Therapy Methods and Clinical Development

Volumn 4, Issue , 2017, Pages 213-224

  Knipping, Friederike ^a   Osborn, Mark J ^b,c   Petri, Karl ^a   Tolar, Jakub ^b,c   Glimm, Hanno ^a   von Kalle, Christof ^a   Schmidt, Manfred ^a   Gabriel, Richard ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Asan Minnesota Institute for Innovating Transplantation   (South Korea)

Author keywords

gene editing; off target; T cell therapy

Indexed keywords

GUIDE RNA; LENTIVIRUS VECTOR; MESSENGER RNA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; GENE INACTIVATION; GENE TARGETING; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURAL HOMOLOGY; T LYMPHOCYTE; TRANSGENE;

EID: 85015755082     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1016/j.omtm.2017.01.005     Document Type: Article

References (53)

1. 1 Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
2. 2 Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114 (2009), 535–546.
3. 3 Heemskerk, M.H., Hagedoorn, R.S., van der Hoorn, M.A., van der Veken, L.T., Hoogeboom, M., Kester, M.G., Willemze, R., Falkenburg, J.H., Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109 (2007), 235–243.
4. 4 Bendle, G.M., Linnemann, C., Hooijkaas, A.I., Bies, L., de Witte, M.A., Jorritsma, A., Kaiser, A.D., Pouw, N., Debets, R., Kieback, E., et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med 16 (2010), 565–570 1p following 570.
5. 5 van Loenen, M.M., de Boer, R., Amir, A.L., Hagedoorn, R.S., Volbeda, G.L., Willemze, R., van Rood, J.J., Falkenburg, J.H., Heemskerk, M.H., Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. USA 107 (2010), 10972–10977.
6. 6 Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.Q., Reik, A., Chu, V., Paschon, D.E., Zhang, L., Kuball, J., et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18 (2012), 807–815.
7. 7 Miller, J.C., Tan, S., Qiao, G., Barlow, K.A., Wang, J., Xia, D.F., Meng, X., Paschon, D.E., Leung, E., Hinkley, S.J., et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29 (2011), 143–148.
8. 8 Rouet, P., Smih, F., Jasin, M., Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol. Cell. Biol. 14 (1994), 8096–8106.
9. 9 Cermak, T., Doyle, E.L., Christian, M., Wang, L., Zhang, Y., Schmidt, C., Baller, J.A., Somia, N.V., Bogdanove, A.J., Voytas, D.F., Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res., 39, 2011, e82.
10. 10 Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., Zhang, F., Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
11. 11 Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., Church, G.M., RNA-guided human genome engineering via Cas9. Science 339 (2013), 823–826.
12. 12 Fine, E.J., Cradick, T.J., Zhao, C.L., Lin, Y., Bao, G., An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Res., 42, 2014, e42.
13. 13 Pattanayak, V., Ramirez, C.L., Joung, J.K., Liu, D.R., Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat. Methods 8 (2011), 765–770.
14. 14 Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., Sander, J.D., High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31 (2013), 822–826.
15. 15 Gabriel, R., Lombardo, A., Arens, A., Miller, J.C., Genovese, P., Kaeppel, C., Nowrouzi, A., Bartholomae, C.C., Wang, J., Friedman, G., et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 29 (2011), 816–823.
16. 16 Wang, X., Wang, Y., Wu, X., Wang, J., Wang, Y., Qiu, Z., Chang, T., Huang, H., Lin, R.J., Yee, J.K., Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 33 (2015), 175–178.
17. 17 Osborn, M.J., Starker, C.G., McElroy, A.N., Webber, B.R., Riddle, M.J., Xia, L., DeFeo, A.P., Gabriel, R., Schmidt, M., von Kalle, C., et al. TALEN-based gene correction for epidermolysis bullosa. Mol. Ther. 21 (2013), 1151–1159.
18. 18 Tsai, S.Q., Zheng, Z., Nguyen, N.T., Liebers, M., Topkar, V.V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A.J., Le, L.P., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33 (2015), 187–197.
19. 19 Frock, R.L., Hu, J., Meyers, R.M., Ho, Y.J., Kii, E., Alt, F.W., Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat. Biotechnol. 33 (2015), 179–186.
20. 20 Osborn, M.J., Webber, B.R., Knipping, F., Lonetree, C.L., Tennis, N., DeFeo, A.P., McElroy, A.N., Starker, C.G., Lee, C., Merkel, S., et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL nucleases. Mol. Ther. 24 (2016), 570–581.
21. 21 Berdien, B., Mock, U., Atanackovic, D., Fehse, B., TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 21 (2014), 539–548.
22. 22 Bunse, M., Bendle, G.M., Linnemann, C., Bies, L., Schulz, S., Schumacher, T.N., Uckert, W., RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol. Ther. 22 (2014), 1983–1991.
23. 23 Carlson, D.F., Tan, W., Lillico, S.G., Stverakova, D., Proudfoot, C., Christian, M., Voytas, D.F., Long, C.R., Whitelaw, C.B., Fahrenkrug, S.C., Efficient TALEN-mediated gene knockout in livestock. Proc. Natl. Acad. Sci. USA 109 (2012), 17382–17387.
24. 24 Hermann, M., Cermak, T., Voytas, D.F., Pelczar, P., Mouse genome engineering using designer nucleases. J. Vis. Exp.(86), 2014, e50930.
25. 25 Christian, M., Cermak, T., Doyle, E.L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A.J., Voytas, D.F., Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186 (2010), 757–761.
26. 26 Mussolino, C., Morbitzer, R., Lütge, F., Dannemann, N., Lahaye, T., Cathomen, T., A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39 (2011), 9283–9293.
27. 27 Bedell, V.M., Wang, Y., Campbell, J.M., Poshusta, T.L., Starker, C.G., Krug, R.G. 2nd, Tan, W., Penheiter, S.G., Ma, A.C., Leung, A.Y., et al. In vivo genome editing using a high-efficiency TALEN system. Nature 491 (2012), 114–118.
28. 28 Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.L., Rupniewski, I., Beausejour, C.M., Waite, A.J., Wang, N.S., Kim, K.A., et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 25 (2007), 778–785.
29. 29 Cade, L., Reyon, D., Hwang, W.Y., Tsai, S.Q., Patel, S., Khayter, C., Joung, J.K., Sander, J.D., Peterson, R.T., Yeh, J.R., Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs. Nucleic Acids Res. 40 (2012), 8001–8010.
30. 30 Nakajima, K., Yaoita, Y., Comparison of TALEN scaffolds in Xenopus tropicalis. Biol. Open 2 (2013), 1364–1370.
31. 31 Zhao, Y., Zheng, Z., Cohen, C.J., Gattinoni, L., Palmer, D.C., Restifo, N.P., Rosenberg, S.A., Morgan, R.A., High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13 (2006), 151–159.
32. 32 Schmidt, M., Schwarzwaelder, K., Bartholomae, C., Zaoui, K., Ball, C., Pilz, I., Braun, S., Glimm, H., von Kalle, C., High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat. Methods 4 (2007), 1051–1057.
33. 33 Arens, A., Appelt, J.U., Bartholomae, C.C., Gabriel, R., Paruzynski, A., Gustafson, D., Cartier, N., Aubourg, P., Deichmann, A., Glimm, H., et al. Bioinformatic clonality analysis of next-generation sequencing-derived viral vector integration sites. Hum. Gene Ther. Methods 23 (2012), 111–118.
34. 34 Paruzynski, A., Arens, A., Gabriel, R., Bartholomae, C.C., Scholz, S., Wang, W., Wolf, S., Glimm, H., Schmidt, M., von Kalle, C., Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat. Protoc. 5 (2010), 1379–1395.
35. 35 Gabriel, R., Eckenberg, R., Paruzynski, A., Bartholomae, C.C., Nowrouzi, A., Arens, A., Howe, S.J., Recchia, A., Cattoglio, C., Wang, W., et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 15 (2009), 1431–1436.
36. 36 Dsouza, M., Larsen, N., Overbeek, R., Searching for patterns in genomic data. Trends Genet. 13 (1997), 497–498.
37. 37 Pinello, L., Canver, M.C., Hoban, M.D., Orkin, S.H., Kohn, D.B., Bauer, D.E., Yuan, G.C., Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol. 34 (2016), 695–697.
38. 38 Hsu, P.D., Scott, D.A., Weinstein, J.A., Ran, F.A., Konermann, S., Agarwala, V., Li, Y., Fine, E.J., Wu, X., Shalem, O., et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31 (2013), 827–832.
39. 39 Cradick, T.J., Qiu, P., Lee, C.M., Fine, E.J., Bao, G., COSMID: a web-based tool for identifying and validating CRISPR/Cas off-target sites. Mol. Ther. Nucleic Acids, 3, 2014, e214.
40. 40 Sommermeyer, D., Uckert, W., Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J. Immunol. 184 (2010), 6223–6231.
41. 41 Bialer, G., Horovitz-Fried, M., Ya'acobi, S., Morgan, R.A., Cohen, C.J., Selected murine residues endow human TCR with enhanced tumor recognition. J. Immunol. 184 (2010), 6232–6241.
42. 42 Scholten, K.B., Kramer, D., Kueter, E.W., Graf, M., Schoedl, T., Meijer, C.J., Schreurs, M.W., Hooijberg, E., Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 119 (2006), 135–145.
43. 43 Kuball, J., Dossett, M.L., Wolfl, M., Ho, W.Y., Voss, R.H., Fowler, C., Greenberg, P.D., Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109 (2007), 2331–2338.
44. 44 Cohen, C.J., Li, Y.F., El-Gamil, M., Robbins, P.F., Rosenberg, S.A., Morgan, R.A., Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67 (2007), 3898–3903.
45. 45 Christian, M.L., Demorest, Z.L., Starker, C.G., Osborn, M.J., Nyquist, M.D., Zhang, Y., Carlson, D.F., Bradley, P., Bogdanove, A.J., Voytas, D.F., Targeting G with TAL effectors: a comparison of activities of TALENs constructed with NN and NK repeat variable di-residues. PLoS ONE, 7, 2012, e45383.
46. 46 Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell Immunotherapies. Cancer Res. 75 (2015), 3853–3864.
47. 47 Wang, Z., Troilo, P.J., Wang, X., Griffiths, T.G., Pacchione, S.J., Barnum, A.B., Harper, L.B., Pauley, C.J., Niu, Z., Denisova, L., et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 11 (2004), 711–721.
48. 48 Mussolino, C., Alzubi, J., Fine, E.J., Morbitzer, R., Cradick, T.J., Lahaye, T., Bao, G., Cathomen, T., TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res. 42 (2014), 6762–6773.
49. 49 Young, C.S., Hicks, M.R., Ermolova, N.V., Nakano, H., Jan, M., Younesi, S., Karumbayaram, S., Kumagai-Cresse, C., Wang, D., Zack, J.A., et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18 (2016), 533–540.
50. 50 Gabriel, R., von Kalle, C., Schmidt, M., Mapping the precision of genome editing. Nat. Biotechnol. 33 (2015), 150–152.
51. 51 Doyle, E.L., Booher, N.J., Standage, D.S., Voytas, D.F., Brendel, V.P., Vandyk, J.K., Bogdanove, A.J., TAL effector-nucleotide targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res. 40 (2012), W117–W122.
52. 52 Lombardo, A., Genovese, P., Beausejour, C.M., Colleoni, S., Lee, Y.L., Kim, K.A., Ando, D., Urnov, F.D., Galli, C., Gregory, P.D., et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25 (2007), 1298–1306.
53. 53 Giudicelli, V., Chaume, D., Lefranc, M.P., IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res. 33 (2005), D256–D261.